PL3689913T3 - Zastosowanie inhibitora PCSK9 do leczenia hiperlipidemii - Google Patents

Zastosowanie inhibitora PCSK9 do leczenia hiperlipidemii

Info

Publication number
PL3689913T3
PL3689913T3 PL19210918T PL19210918T PL3689913T3 PL 3689913 T3 PL3689913 T3 PL 3689913T3 PL 19210918 T PL19210918 T PL 19210918T PL 19210918 T PL19210918 T PL 19210918T PL 3689913 T3 PL3689913 T3 PL 3689913T3
Authority
PL
Poland
Prior art keywords
pcsk9 inhibitor
treat hyperlipidemia
hyperlipidemia
treat
pcsk9
Prior art date
Application number
PL19210918T
Other languages
English (en)
Polish (pl)
Inventor
Marie BACCARA-DINET
Laurence BESSAC
Umesh CHAUDHARI
Corinne Hanotin
Robert C. Pordy
William J. Sasiela
Daniel A. Schwemmer Gipe
Original Assignee
Sanofi Biotechnology
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology, Regeneron Pharmaceuticals, Inc. filed Critical Sanofi Biotechnology
Publication of PL3689913T3 publication Critical patent/PL3689913T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Emergency Medicine (AREA)
PL19210918T 2013-10-11 2014-10-10 Zastosowanie inhibitora PCSK9 do leczenia hiperlipidemii PL3689913T3 (pl)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201361890154P 2013-10-11 2013-10-11
US201461923103P 2014-01-02 2014-01-02
US201461955514P 2014-03-19 2014-03-19
US201462004620P 2014-05-29 2014-05-29
US201462025104P 2014-07-16 2014-07-16
EP14306221 2014-07-31
US201462054571P 2014-09-24 2014-09-24
EP14306584 2014-10-09
EP19210918.9A EP3689913B1 (en) 2013-10-11 2014-10-10 Use of a pcsk9 inhibitor to treat hyperlipidemia
EP14802527.3A EP3055333B1 (en) 2013-10-11 2014-10-10 Use of a pcsk9 inhibitor to treat hyperlipidemia
PCT/US2014/060109 WO2015054619A2 (en) 2013-10-11 2014-10-10 Use of a pcsk9 inhibitor to treat hyperlipidemia

Publications (1)

Publication Number Publication Date
PL3689913T3 true PL3689913T3 (pl) 2022-07-04

Family

ID=52813751

Family Applications (2)

Application Number Title Priority Date Filing Date
PL19210918T PL3689913T3 (pl) 2013-10-11 2014-10-10 Zastosowanie inhibitora PCSK9 do leczenia hiperlipidemii
PL14802527T PL3055333T4 (pl) 2013-10-11 2014-10-10 Wykorzystanie inhibitora pcsk9 do leczenia hyperlipidemii

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL14802527T PL3055333T4 (pl) 2013-10-11 2014-10-10 Wykorzystanie inhibitora pcsk9 do leczenia hyperlipidemii

Country Status (14)

Country Link
US (1) US20150140002A1 (OSRAM)
EP (2) EP3055333B1 (OSRAM)
JP (2) JP6846931B2 (OSRAM)
KR (3) KR20160062166A (OSRAM)
CN (3) CN115154599A (OSRAM)
AU (2) AU2014331754B2 (OSRAM)
CA (1) CA2926942A1 (OSRAM)
EA (1) EA037526B1 (OSRAM)
ES (1) ES2914978T3 (OSRAM)
IL (1) IL244995B (OSRAM)
MX (3) MX373298B (OSRAM)
PL (2) PL3689913T3 (OSRAM)
TW (1) TWI669131B (OSRAM)
WO (1) WO2015054619A2 (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
AR084938A1 (es) 2011-01-28 2013-07-10 Sanofi Sa Anticuerpos humanos contra la proproteina convertasa subtilisina/kexina tipo 9 (anti pcsk9) para usar en metodos para tratar grupos de pacientes
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2773111T3 (es) 2011-09-16 2020-07-09 Regeneron Pharma Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a)
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
US10058630B2 (en) * 2012-10-22 2018-08-28 Concievalve, Llc Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TW201534324A (zh) 2013-06-07 2015-09-16 Sanofi Sa 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
CN106062003A (zh) 2013-11-12 2016-10-26 赛诺菲生物技术公司 用于与pcsk9抑制剂一起使用的给药方案
AU2015289874A1 (en) * 2014-07-14 2017-02-02 Amgen Inc. Crystalline antibody formulations
KR20240017117A (ko) 2014-07-16 2024-02-06 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
JP2018516624A (ja) * 2015-04-15 2018-06-28 コンシーヴァルブ エルエルシー 自然心臓弁、ステント装着された心臓弁またはバイオプロテーゼの狭窄、閉塞または石灰化を抑制するためのデバイスおよび方法
CN104861071B (zh) * 2015-04-27 2019-04-12 南京师范大学 针对pcsk9的全人源单克隆抗体的可变区基因及其应用
EA201890519A1 (ru) 2015-08-18 2018-07-31 Ридженерон Фармасьютикалз, Инк. Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов
JP2020502991A (ja) 2016-09-20 2020-01-30 ウーシー バイオロジクス アイルランド リミテッド 新規抗ｐｃｓｋ９抗体
BR112019020148A2 (pt) 2017-04-13 2020-05-05 Cadila Healthcare Ltd peptídeo
WO2018200489A1 (en) 2017-04-25 2018-11-01 The Brigham And Women’S Hospital, Inc. Il-8, il-6, il-1b and tet2 and dnmt3a in atherosclerosis
CN107090474A (zh) * 2017-05-22 2017-08-25 山东大学 一种腹主动脉瘤疾病动物模型的制备方法
CN109963877B (zh) * 2017-06-14 2023-01-20 江苏恒瑞医药股份有限公司 Pcsk9抗体、其抗原结合片段及其医药用途
TW202521589A (zh) * 2018-03-06 2025-06-01 法商賽諾菲生物技術公司 降低心血管風險的方法
JOP20190150A1 (ar) 2018-06-21 2019-12-21 Merck Sharp & Dohme مركبات مناهضة لـ pcsk9
US11248001B2 (en) 2019-01-18 2022-02-15 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
US20230312750A1 (en) * 2019-11-18 2023-10-05 Ad Pharmaceuticals Co., Ltd. Anti-pcsk9 antibody and use thereof
US20230272112A1 (en) * 2019-12-10 2023-08-31 Regeneron Pharmaceuticals, Inc. Use of a pcsk9 inhibitor to treat homozygous familial hypercholesterolemia
CN114277032A (zh) * 2021-12-31 2022-04-05 华中科技大学同济医学院附属协和医院 一种低密度脂蛋白受体基因突变体及其应用
CN116983434B (zh) * 2023-09-28 2024-03-15 康霖生物科技（杭州）有限公司 用于基因治疗的核酸构建体及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) * 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
US8357371B2 (en) * 2008-12-15 2013-01-22 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to PCSK9
AR084938A1 (es) * 2011-01-28 2013-07-10 Sanofi Sa Anticuerpos humanos contra la proproteina convertasa subtilisina/kexina tipo 9 (anti pcsk9) para usar en metodos para tratar grupos de pacientes
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20130006482A1 (en) * 2011-06-30 2013-01-03 Ramadev Burigsay Hukkeri Guidance system for a mobile machine
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2773111T3 (es) * 2011-09-16 2020-07-09 Regeneron Pharma Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a)
TWI682780B (zh) * 2013-05-30 2020-01-21 美商再生元醫藥公司 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途

Also Published As

Publication number Publication date
AU2020203636B2 (en) 2023-05-18
EP3055333A2 (en) 2016-08-17
WO2015054619A8 (en) 2016-03-31
KR20220048051A (ko) 2022-04-19
TW201605475A (zh) 2016-02-16
WO2015054619A3 (en) 2015-06-04
CN115192704A (zh) 2022-10-18
PL3055333T3 (pl) 2020-06-01
AU2014331754B2 (en) 2020-06-18
JP2019214594A (ja) 2019-12-19
AU2020203636A1 (en) 2020-06-25
MX2016004580A (es) 2016-12-08
WO2015054619A2 (en) 2015-04-16
JP6846931B2 (ja) 2021-03-24
EP3055333B1 (en) 2019-12-04
AU2014331754A1 (en) 2016-05-26
CA2926942A1 (en) 2015-04-16
EA201690754A1 (ru) 2016-10-31
US20150140002A1 (en) 2015-05-21
KR20160062166A (ko) 2016-06-01
IL244995B (en) 2019-12-31
CN105814085A (zh) 2016-07-27
MX373298B (es) 2020-05-20
KR20230119045A (ko) 2023-08-14
CN115154599A (zh) 2022-10-11
MX2022013172A (es) 2022-11-30
MX2020004023A (es) 2020-08-13
ES2914978T3 (es) 2022-06-20
EA037526B1 (ru) 2021-04-08
PL3055333T4 (pl) 2020-07-27
TWI669131B (zh) 2019-08-21
JP2016538248A (ja) 2016-12-08
JP6994484B2 (ja) 2022-02-04
EP3689913A1 (en) 2020-08-05
EP3689913B1 (en) 2022-03-23
IL244995A0 (en) 2016-05-31

Similar Documents

Publication Publication Date Title
IL244995A0 (en) Using pcsk9 inhibitor to treat hyperlipidemia
IL279682A (en) Benzoquinolone compounds as VMAT2 inhibitors
RS63939B1 (sr) Inhibitori lizin specifične demetilaze-1
EP2948450A4 (en) METALLOENZYMINHIBITORVERBINDUNGEN
ZA201702252B (en) A selective inhibitor of prosphatidylinositol 3-kinase-gamma
PT3293176T (pt) Forma cristalina de um inibidor de pde4
DK2928477T3 (da) Anvendelse af telomeraseinhibitor imetelstat til behandling af myelofibrosis
EP2958964A4 (en) TREATMENT OF FREQUENTLY AFFECTED SURFACES TO IMPROVE HYGIENE
EP2962186A4 (en) PROVISION OF CODE CHANGE JOB PACKAGES OF VARIOUS SIZE FOR VALIDATORS
ZA201409181B (en) Treatment of waste water
ZA202207530B (en) Use of phenoxypropylamine compounds to treat depression
IL244617A0 (en) Benzoquinolone compounds as vmat2 inhibitors
IL240763B (en) The halopyrazoles as thrombin inhibitors
PL2888228T3 (pl) Inhibitory oddziaływania CD40-TRAF6
PT3055333T (pt) Uso de um inibidor de pcsk9 para tratar a hiperlipidemia
PT3689913T (pt) Uso de um inibidor de pcsk9 para tratar a hiperlipidemia
ZA201409002B (en) Treatment of waste water
GB201308117D0 (en) Inhibitor of calcifying disorders
GB201322036D0 (en) New therapeutic uses of enzyme inhibitors
GB201310488D0 (en) New therapeutic uses of enzyme inhibitors